Horizon's Tepezza Broke The Mold For 2020 Launches, But Still Got Snared By COVID-19
An Interview With CEO Tim Walbert
Tepezza was the breakout launch of the year and will change Horizon's growth trajectory, but for now it has been sidelined by a supply constraint caused by COVID-19 vaccine manufacturing.
You may also be interested in...
Dazodalibep Expands Horizons With Phase II Sjögren’s Syndrome Data
A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj
Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.